Dr. West questions Dr. Gideon Blumenthal of the FDA about how he and his team there struggle to provide timely access to emerging cancer treatments, while also debating questions of the proper thresholds for efficacy and safety. (20:15)
Dr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC. (18:00)
